Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma
Objective: to study the efficacy and safety of the antitumor RVP program (lenalidomide, bortezomib, prednisone) as a first-line therapy in patients with multiple myeloma (MM). Materials and methods. A prospective study involved 39 patients with MM (15 women, 24 men), median age 61 years (30–76 years...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2019-04-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/331 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849241272810733568 |
|---|---|
| author | K. A. Belousov T. A. Mitina Yu. Yu. Chuksina A. K. Golenkov E. V. Kataeva E. V. Trifonova Yu. B. Chernykh L. L. Vysotskaya S. G. Zakharov E. F. Klinushkina A. N. Mitin |
| author_facet | K. A. Belousov T. A. Mitina Yu. Yu. Chuksina A. K. Golenkov E. V. Kataeva E. V. Trifonova Yu. B. Chernykh L. L. Vysotskaya S. G. Zakharov E. F. Klinushkina A. N. Mitin |
| author_sort | K. A. Belousov |
| collection | DOAJ |
| description | Objective: to study the efficacy and safety of the antitumor RVP program (lenalidomide, bortezomib, prednisone) as a first-line therapy in patients with multiple myeloma (MM). Materials and methods. A prospective study involved 39 patients with MM (15 women, 24 men), median age 61 years (30–76 years). All patients had Durie–Salmon stage III disease. According to the paraprotein isotype variant, 19 patients (48.7 %) had Gk myeloma, 8 (20.5 %) had Gλ, 4 (10.2 %) – Ak, 1 – Aλ, 1 – Dk, 1 – paraproteinemia Bens-Jones k and 1 – Bens-Jones λ, 2 – Dλ, and 2 patients – nonsecreting MM. The average level of plasma cells in the bone marrow was 31.7 % (0.8–80.0 %). In 14 (35.8 %) patients there were plasmacytomas of various localization (spine, cranial bones, clavicle, pleura). Nine (23.0 %) patients had renal failure, requiring the start of renal replacement therapy. The average Karnovsky index in the study group was 50 %. All patients received RVP therapy (lenalidomide 25 mg in 1–14 days, bortezomib 1.3 mg subcutaneously in 1, 4, 8, 11 days, prednisolone 60 mg/m2; the interval between courses was 42 days) as the first line therapy. Evaluation of therapy efficacy, characterized by overall survival, objective response rates (the number of complete, very good partial and partial remissions) was performed after 6 treatment courses. Results. The median follow-up was 15 months; the median of overall survival was not achieved. Objective antitumor response achieved in 29 (74.3 %) patients, including complete remissions in 3 (7.6 %), very good partial remissions – in 7 (17.9 %), partial remissions – in 19 (48.7 %) patients. In 2 out of 9 patients who received renal replacement therapy, independence from dialysis therapy was achieved. Cases of III–IV stage hematological and non-hematological toxicity in the study were not noted. Conclusion. The antitumor RVP program showed high efficacy and safety as a first-line therapy in a non-selective group of patients, including those with a complicated MM course. |
| format | Article |
| id | doaj-art-9d44a6473ca940b5939c7131d1ff3f5b |
| institution | Kabale University |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| publishDate | 2019-04-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj-art-9d44a6473ca940b5939c7131d1ff3f5b2025-08-20T04:00:13ZrusABV-pressОнкогематология1818-83462413-40232019-04-01141141910.17650/1818-8346-2019-14-1-14-19300Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myelomaK. A. Belousov0T. A. Mitina1Yu. Yu. Chuksina2A. K. Golenkov3E. V. Kataeva4E. V. Trifonova5Yu. B. Chernykh6L. L. Vysotskaya7S. G. Zakharov8E. F. Klinushkina9A. N. Mitin10M.F. Vladimirskiy Moscow Regional Research and Clinical Institute; 61/2 Shchepkina St., Moscow 129110M.F. Vladimirskiy Moscow Regional Research and Clinical Institute; 61/2 Shchepkina St., Moscow 129110M.F. Vladimirskiy Moscow Regional Research and Clinical Institute; 61/2 Shchepkina St., Moscow 129110M.F. Vladimirskiy Moscow Regional Research and Clinical Institute; 61/2 Shchepkina St., Moscow 129110M.F. Vladimirskiy Moscow Regional Research and Clinical Institute; 61/2 Shchepkina St., Moscow 129110M.F. Vladimirskiy Moscow Regional Research and Clinical Institute; 61/2 Shchepkina St., Moscow 129110M.F. Vladimirskiy Moscow Regional Research and Clinical Institute; 61/2 Shchepkina St., Moscow 129110M.F. Vladimirskiy Moscow Regional Research and Clinical Institute; 61/2 Shchepkina St., Moscow 129110M.F. Vladimirskiy Moscow Regional Research and Clinical Institute; 61/2 Shchepkina St., Moscow 129110M.F. Vladimirskiy Moscow Regional Research and Clinical Institute; 61/2 Shchepkina St., Moscow 129110State Scientific Center “Institute of Immunology”, Federal Medical and Biological Agency; 24 Kashirskoe Shosse, Moscow 115478Objective: to study the efficacy and safety of the antitumor RVP program (lenalidomide, bortezomib, prednisone) as a first-line therapy in patients with multiple myeloma (MM). Materials and methods. A prospective study involved 39 patients with MM (15 women, 24 men), median age 61 years (30–76 years). All patients had Durie–Salmon stage III disease. According to the paraprotein isotype variant, 19 patients (48.7 %) had Gk myeloma, 8 (20.5 %) had Gλ, 4 (10.2 %) – Ak, 1 – Aλ, 1 – Dk, 1 – paraproteinemia Bens-Jones k and 1 – Bens-Jones λ, 2 – Dλ, and 2 patients – nonsecreting MM. The average level of plasma cells in the bone marrow was 31.7 % (0.8–80.0 %). In 14 (35.8 %) patients there were plasmacytomas of various localization (spine, cranial bones, clavicle, pleura). Nine (23.0 %) patients had renal failure, requiring the start of renal replacement therapy. The average Karnovsky index in the study group was 50 %. All patients received RVP therapy (lenalidomide 25 mg in 1–14 days, bortezomib 1.3 mg subcutaneously in 1, 4, 8, 11 days, prednisolone 60 mg/m2; the interval between courses was 42 days) as the first line therapy. Evaluation of therapy efficacy, characterized by overall survival, objective response rates (the number of complete, very good partial and partial remissions) was performed after 6 treatment courses. Results. The median follow-up was 15 months; the median of overall survival was not achieved. Objective antitumor response achieved in 29 (74.3 %) patients, including complete remissions in 3 (7.6 %), very good partial remissions – in 7 (17.9 %), partial remissions – in 19 (48.7 %) patients. In 2 out of 9 patients who received renal replacement therapy, independence from dialysis therapy was achieved. Cases of III–IV stage hematological and non-hematological toxicity in the study were not noted. Conclusion. The antitumor RVP program showed high efficacy and safety as a first-line therapy in a non-selective group of patients, including those with a complicated MM course.https://oncohematology.abvpress.ru/ongm/article/view/331multiple myelomafirst-line therapylenalidomidebortezomibpolichemotherapy |
| spellingShingle | K. A. Belousov T. A. Mitina Yu. Yu. Chuksina A. K. Golenkov E. V. Kataeva E. V. Trifonova Yu. B. Chernykh L. L. Vysotskaya S. G. Zakharov E. F. Klinushkina A. N. Mitin Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma Онкогематология multiple myeloma first-line therapy lenalidomide bortezomib polichemotherapy |
| title | Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma |
| title_full | Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma |
| title_fullStr | Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma |
| title_full_unstemmed | Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma |
| title_short | Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma |
| title_sort | efficiency of lenalidomide bortezomib and prednisone rvp in patients with newly diagnosed multiple myeloma |
| topic | multiple myeloma first-line therapy lenalidomide bortezomib polichemotherapy |
| url | https://oncohematology.abvpress.ru/ongm/article/view/331 |
| work_keys_str_mv | AT kabelousov efficiencyoflenalidomidebortezomibandprednisonervpinpatientswithnewlydiagnosedmultiplemyeloma AT tamitina efficiencyoflenalidomidebortezomibandprednisonervpinpatientswithnewlydiagnosedmultiplemyeloma AT yuyuchuksina efficiencyoflenalidomidebortezomibandprednisonervpinpatientswithnewlydiagnosedmultiplemyeloma AT akgolenkov efficiencyoflenalidomidebortezomibandprednisonervpinpatientswithnewlydiagnosedmultiplemyeloma AT evkataeva efficiencyoflenalidomidebortezomibandprednisonervpinpatientswithnewlydiagnosedmultiplemyeloma AT evtrifonova efficiencyoflenalidomidebortezomibandprednisonervpinpatientswithnewlydiagnosedmultiplemyeloma AT yubchernykh efficiencyoflenalidomidebortezomibandprednisonervpinpatientswithnewlydiagnosedmultiplemyeloma AT llvysotskaya efficiencyoflenalidomidebortezomibandprednisonervpinpatientswithnewlydiagnosedmultiplemyeloma AT sgzakharov efficiencyoflenalidomidebortezomibandprednisonervpinpatientswithnewlydiagnosedmultiplemyeloma AT efklinushkina efficiencyoflenalidomidebortezomibandprednisonervpinpatientswithnewlydiagnosedmultiplemyeloma AT anmitin efficiencyoflenalidomidebortezomibandprednisonervpinpatientswithnewlydiagnosedmultiplemyeloma |